DOCSLIB.ORG

Amphetamines and Designer Drugs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Amphetamines and Designer Drugs Amphetamines and designer drugs The term designer drug refers to chemicals that are synthesised with the intention to bypass drug legislations. This is usually done by modi- fying the molecular structure without loosing the subjective effects one gets from the original drug. In the last decade there has been a massi- ve increase in the amount of designer drugs sold via the internet. Many of the chemicals fall under the various drug analogue legislations in certain countries, but most countries have no general analogue act or equivalent legislation. Novel compounds often fall outside of the law after only minor structural modifications. The most important groups of designer drugs are amphetamine derivates like MDMA and other Ecstasy compounds, phenylcyclidin, fenta- nyl derivates, petidin derivates and designer cannabinoids, also known as Spice-compounds (See our BMF 44-Spice). Chiron proudly presents a wide range of reference ma- terials of designer drugs. We are continuously expanding our product range. On the following pages you will find an overview of our current selection. Please inquire for prices or more information. x HCl x HCl Chiron No. 9160.10 Chiron No. 9155.9 Chiron No. 9164.11 MDMA Methamphetamine Amphetamine (free (Ecstacy) hydrochloride hydrochloride base) www.chiron.no [email protected] Tel.:+4773874490 Fax:+4773874499 BMFocus 46_v5 p.1/4, 05-12 Chiron No. Product Concentration Solvent Quantity Amphetamine 9155.9-100-ME DL-Amphetamine, free base 100µg base/mL MeOH 1mL 9155.9-K-ME DL-Amphetamine, free base 1000µg base/mL MeOH 1mL 9155.9-10MG DL-Amphetamine, free base neat neat 10mg 9156.9-100-ME DL-Amphetamine hydrochloride 100µg base/mL MeOH 1mL 9156.9-K-ME DL-Amphetamine hydrochloride 1000µg base/mL MeOH 1mL 9156.9-10MG DL-Amphetamine hydrochloride neat neat 10mg 9158.9-100-ME DL-Amphetamine-d5 hydrochloride 100µg base/mL MeOH 1mL 9158.9-K-ME DL-Amphetamine-d5 hydrochloride 1000µg base/mL MeOH 1mL 9158.9-10MG DL-Amphetamine-d5 hydrochloride neat neat 10mg 9157.9-100-ME DL-Amphetamine sulfate 100µg base/mL MeOH 1mL 9157.9-K-ME DL-Amphetamine sulfate 1000µg base/mL MeOH 1mL 9157.9-10MG DL-Amphetamine sulfate neat neat 10mg 9157.9-50MG DL-Amphetamine sulfate neat neat 50mg 9200.9-100-ME (R)-(-)-Amphetamine hydrochloride 100µg base/mL MeOH 1mL 9200.9-K-ME (R)-(-)-Amphetamine hydrochloride 1000µg base/mL MeOH 1mL 9201.9-100-ME (S)-(+)-Amphetamine hydrochloride 100µg base/mL MeOH 1mL 9201.9-K-ME (S)-(+)-Amphetamine hydrochloride 1000µg base/mL MeOH 1mL 9785.9-10MG DL-2-Fluoroamphetamine hydrochloride neat neat 10 MG 9786.9-10MG DL-3-Fluoroamphetamine hydrochloride neat neat 10 MG 9679.9-10MG DL-4-Fluoroamphetamine neat neat 10 MG 9783.10-10MG DL-2-Methoxyamphetamine hydrochloride neat neat 10 MG 9784.10-10MG DL-3-Methoxyamphetamine hydrochloride neat neat 10 MG 9693.10-10MG DL-4-Methoxyamphetamine hydrochloride neat neat 10 MG 9787.10-10MG DL-2-Methylamphetamine hydrochloride neat neat 10 MG 9788.10-10MG DL-3-Methylamphetamine hydrochloride neat neat 10 MG 9789.10-10MG DL-4-Methylamphetamine hydrochloride neat neat 10 MG 6-APB 9809.11-10MG 6-APB hydrochloride neat neat 10mg 9902.11-10MG APB isomer mix (4-APB and 6-APB) neat neat 10mg Bromo-Dragonfly (αR)-8-Bromo-α-methyl-benzo[1,2-b:4,5-b'] 9690.13-100-ME difuran-4-ethanamine hydrochloride 100µg/mL MeOH 1mL (Bromo-Dragonfly hydrochloride) Bromopride 9276.14-K-ME Bromopride 1000µg/mL MeOH 1mL Ephedrine 9150.10-100-ME (1R,2S)-(-)-Ephedrine 100µg/mL MeOH 1mL 8947.10-1G (1R,2S)-(-)-Ephedrine hydrochloride neat neat 1G www.chiron.no [email protected] Tel.:+4773874490 Fax:+4773874499 BMFocus 46_v5 p.2/4, 05-12 Chiron No. Product Concentration Solvent Quant. 9028.10-100-ME (1R,2S)-(-)-Ephedrine-d6 hydrochloride (dimethyl-d6) 100µg/mL MeOH 1mL 9239.10-100-ME (1S,2R)-(+)-Ephedrine hydrochloride 100µg/mL MeOH 1mL 9239.10-1G (1S,2R)-(+)-Ephedrine hydrochloride neat neat 1G 9236.10-100-ME (1S,2R)-(+)-Ephedrine-d3 hydrochloride(N-methyl-d3) 100µg/mL MeOH 1mL Fluspirilene 9748.29-10MG Fluspirilene neat neat 10mg MDA (3,4-Methylenedioxyamphetamine) 9162.10-100-ME (+/-)-MDA hydrochloride 100µg base/mL MeOH 1mL 9162.10-K-ME (+/-)-MDA hydrochloride 1000µg base/mL MeOH 1mL 9162.10-10MG (+/-)-MDA hydrochloride neat neat 10mg 9163.10-100-ME (+/-)-MDA hydrochloride-d5 100µg base/mL MeOH 1mL 9163.10-K-ME (+/-)-MDA hydrochloride-d5 1000µg base/mL MeOH 1mL 9163.10-10MG (+/-)-MDA hydrochloride-d5 neat neat 10mg 9204.10-100-ME D-MDA hydrochloride 100µg base/mL MeOH 1mL 9205.10-100-ME L-MDA hydrochloride 100µg base/mL MeOH 1mL MDAI 9889.10-K-ME 5,6-Methylenedioxy-2-aminoindane 1000µg base/mL MeOH 1mL 9889.10-10MG 5,6-Methylenedioxy-2-aminoindane neat neat 10mg 9940.10-K-ME 5,6-Methylenedioxy-2-aminoindane hydrochloride 1000µg base/mL MeOH 1mL 9940.10-K-ME 5,6-Methylenedioxy-2-aminoindane hydrochloride neat neat 10mg MDEA (3,4-Methylenedioxy-N-ethylamphetamine) 9166.12-100-ME MDEA hydrochloride 100µg base/mL MeOH 1mL 9166.12-K-ME MDEA hydrochloride 1000µg base/mL MeOH 1mL 9166.12-10MG MDEA hydrochloride neat neat 10mg MDMA (3,4-Methylenedioxymethamphetamine) 9164.11-K-ME (+/-)-MDMA hydrochloride 1000µg base/mL MeOH 1mL 9164.11-10MG (+/-)-MDMA hydrochloride neat neat 10mg 9165.11-100-ME (+/-)-MDMA hydrochloride-d5 100µg base/mL MeOH 1mL 9165.11-K-ME (+/-)-MDMA hydrochloride-d5 1000µg base/mL MeOH 1mL 9165.11-10MG (+/-)-MDMA hydrochloride-d5 neat neat 10mg 9206.11-100ME D-MDMA hydrochloride 100µg base/mL MeOH 1mL 9207.11-100-ME L-MDMA hydrochloride 100µg base/mL MeOH 1mL MDPV 9901.16-K-ME 1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1- 100µg base/mL MeOH 1mL pentanone hydrochloride 9901.16-10MG 1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1- neat neat 10mg pentanone hydrochloride Methamphetamine 9160.10-100-ME DL-Methamphetamine hydrochloride 100µg base/mL MeOH 1mL 9160.10-K-ME DL-Methamphetamine hydrochloride 1000µg base/mL MeOH 1mL 9160.10-10MG DL-Methamphetamine hydrochloride neat neat 10mg 9389.10-100-ME DL-Methamphetamine-d3 hydrochloride 100µg base/mL MeOH 1mL www.chiron.no [email protected] Tel.:+4773874490 Fax:+4773874499 BMFocus 46_v5 p.3/4, 05-12 Chiron No. Product Concentration Solvent Quant. Methamphetamine 9161.10-100-ME DL-Methamphetamine-d5 hydrochloride 100µg base/mL MeOH 1mL 9161.10-K-ME DL-Methamphetamine-d5 hydrochloride 1000µg base/mL MeOH 1mL 9161.10-10MG DL-Methamphetamine-d5 hydrochloride neat neat 10mg 9202.10-100-ME (R)-(-)-Methamphetamine hydrochloride 100µg base/mL MeOH 1mL 9202.10-K-ME (R)-(-)-Methamphetamine hydrochloride 1000µg base/mL MeOH 1mL 9202.10-10MG (R)-(-)-Methamphetamine hydrochloride neat neat 10mg 9203.10-100-ME (S)-(+)-Methamphetamine hydrochloride 100µg base/mL MeOH 1mL 9203.10-K-ME (S)-(+)-Methamphetamine hydrochloride 1000µg base/mL MeOH 1mL 9203.10-10MG (S)-(+)-Methamphetamine hydrochloride neat neat 10mg 9790.10-10MG DL-2-Fluoromethamphetamine hydrochloride neat neat 10mg 9791.10-10MG DL-3-Fluoromethamphetamine hydrochloride neat neat 10mg 9323.10-100-ME DL-4-Fluoromethamphetamine hydrochloride 100µg base/mL MeOH 1mL 9323.10-K-ME DL-4-Fluoromethamphetamine hydrochloride 1000µg base/mL MeOH 1mL 9323.10-10MG DL-4-Fluoromethamphetamine hydrochloride neat neat 10mg 9792.11-10MG DL-2-Methoxymethamphetamine hydrochloride neat neat 10mg 9793.11-10MG DL-3-Methoxymethamphetamine hydrochloride neat neat 10mg 9691.11-10MG DL-4-Methoxymethamphetamine hydrochloride neat neat 10mg 9794.11-10MG DL-2-Methylmethamphetamine hydrochloride neat neat 10mg 9795.11-10MG DL-3-Methylmethamphetamine hydrochloride neat neat 10mg 9796.11-10MG DL-4-Methylmethamphetamine hydrochloride neat neat 10mg Methcathinone and derivates 9308.10-10MG Methcathinone hydrochloride neat neat 10mg 9805.13-10MG 4-Hydroxymethcathinone neat neat 10mg 9806.10-10MG 2-Fluoromethcathinone neat neat 10mg 5-MeO-MIPT N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-N- 9985.15-K-ME methylpropan-2-amine 1000µg/mL MeOH 1mL Methylephedrine 9903.11-100-ME (1R,2S)-(-)-N-Methylephedrine 100µg/ml MeOH 1mL Norephedrine and Norspeudoephedrine (Cathine) 9152.9-100-ME (1R,2S)-(-)-Norephedrine 100µg/ml MeOH 1mL 9152.9-100MG (1R,2S)-(-)-Norephedrine neat neat 100mg 9153.9-100MG DL-Norephedrine hydrochloride neat neat 100mg 9210.9-10MG Cathine hydrochloride neat neat 10mg 9210.9-100-ME Cathine hydrochloride 100µg/ml MeOH 1mL Piperazine 9350.4-1G Piperazine neat neat 1g Pseudoephedrine 9151.10-100-ME (1S,2S)-(+)-Pseudoephedrine 100µg/mL MeOH 1mL 9235.10-100-ME (1S,2S)-(+)-Pseudoephedrine-d3 HCl (N-methyl-d3) 100µg/mL MeOH 1mL 9154.10-100-ME (1R,2R)-(-)-Pseudoephedrine 100µg/mL MeOH 1mL 9234.10-100-ME (1R,2R)-(-)-Pseudoephedrine-d3 HCl (N-methyl-d3) 100µg/mL MeOH 1mL Psilocin 9811.18-10MG 4-Acetylpsilocin fumarate neat neat 10mg www.chiron.no [email protected] Tel.:+4773874490 Fax:+4773874499 BMFocus 46_v5 p.4/4, 05-12 .
Load more

Recommended publications
  • An Analytical Perspective on Determination of Free Base Nicotine in E-Liquids
    Virginia Commonwealth University VCU Scholars Compass Pharmaceutics Publications Dept. of Pharmaceutics 2020 An Analytical Perspective on Determination of Free Base Nicotine in E-Liquids Vinit V. Gholap Virginia Commonwealth University Rodrigo S. Heyder Virginia Commonwealth University Leon Kosmider Medical University of Silesia Matthew S. Halquist Virginia Commonwealth University, [email protected] Follow this and additional works at: https://scholarscompass.vcu.edu/pceu_pubs Part of the Pharmacy and Pharmaceutical Sciences Commons Copyright © 2020 Vinit V. Gholap et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Downloaded from https://scholarscompass.vcu.edu/pceu_pubs/19 This Article is brought to you for free and open access by the Dept. of Pharmaceutics at VCU Scholars Compass. It has been accepted for inclusion in Pharmaceutics Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Hindawi Journal of Analytical Methods in Chemistry Volume 2020, Article ID 6178570, 12 pages https://doi.org/10.1155/2020/6178570 Research Article An Analytical Perspective on Determination of Free Base Nicotine in E-Liquids Vinit V. Gholap ,1 Rodrigo S. Heyder,2 Leon Kosmider,3 and Matthew S. Halquist 1 1Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond 23298, VA, USA 2Department of Pharmaceutics, Pharmaceutical Engineering, School of Pharmacy, Virginia Commonwealth University, Richmond 23298, VA, USA 3Department of General and Inorganic Chemistry, Medical University of Silesia, Katowice FOPS in Sosnowiec, Jagiellonska 4, 41-200 Sosnowiec, Poland Correspondence should be addressed to Matthew S.
    [Show full text]
  • The Stimulants and Hallucinogens Under Consideration: a Brief Overview of Their Chemistry and Pharmacology
    Drug and Alcohol Dependence, 17 (1986) 107-118 107 Elsevier Scientific Publishers Ireland Ltd. THE STIMULANTS AND HALLUCINOGENS UNDER CONSIDERATION: A BRIEF OVERVIEW OF THEIR CHEMISTRY AND PHARMACOLOGY LOUIS S. HARRIS Dcparlmcnl of Pharmacology, Medical College of Virginia, Virginia Commonwealth Unwersity, Richmond, VA 23298 (U.S.A.) SUMMARY The substances under review are a heterogenous set of compounds from a pharmacological point of view, though many have a common phenylethyl- amine structure. Variations in structure lead to marked changes in potency and characteristic action. The introductory material presented here is meant to provide a set of chemical and pharmacological highlights of the 28 substances under con- sideration. The most commonly used names or INN names, Chemical Abstract (CA) names and numbers, and elemental formulae are provided in the accompanying figures. This provides both some basic information on the substances and a starting point for the more detailed information that follows in the individual papers by contributors to the symposium. Key words: Stimulants, their chemistry and pharmacology - Hallucinogens, their chemistry and pharmacology INTRODUCTION Cathine (Fig. 1) is one of the active principles of khat (Catha edulis). The structure has two asymmetric centers and exists as two geometric isomers, each of which has been resolved into its optical isomers. In the plant it exists as d-nor-pseudoephedrine. It is a typical sympathomimetic amine with a strong component of amphetamine-like activity. The racemic mixture is known generically in this country and others as phenylpropanolamine (dl- norephedrine). It is widely available as an over-the-counter (OTC) anti- appetite agent and nasal decongestant.
    [Show full text]
  • KHAT Latest Revision: June 11, 2005
    KHAT Latest Revision: June 11, 2005 O CH3 NH2 Cathinone OH CH3 NH2 Cathine N CH3 H3C N 3,6-dimethyl-2,5-diphenylpyrazine (dimer of Cathinone) 1. SYNONYMS CFR: Cathinone Cathine CAS #: Cathinone Hydrochloride: 71031-15-7 Cathine Hydrochloride: 2153-98-2 Cathine Base: 492-39-7 Other Names: Catha edulis Kat Mutsawhari Mutsawari Mdimamadzi Musitate Mirungi Miraa Ol meraa Tumayot Liruti Ikwa Arabian Tea 2. CHEMICAL AND PHYSICAL DATA Khat is used as a stimulant or as a medicine in parts of Africa and the Arabian Peninsula. The plant is thought to have been in cultivation before the coffee plant; historical references date the use of the plant to the fourteenth century. Peter Forsskal, a physician and botanist, collected khat specimens in an expedition organized by the King of Denmark in the eighteenth century. Forsskal assigned the name Catha edulis to the plant. The effects produced by the drug include excitation, hypersensitivity, anorexia, insomnia, euphoria, increased respiration, and hyperthermia. These effects closely parallel the effects of d-amphetamine. Khat is a bush or tree that grows naturally in the humid mountainous regions (elevations of 5000 to 6500 feet) of East and South Africa. The trees can grow naturally to over 60 ft; however, cultivated khat trees are pruned and their height to kept to approximately 16 feet. Khat also grows to a height of 3 feet as a small bush in arid regions. Like opium, the alkaloid content of khat will vary with the soil, climatic conditions, and cultivation. Khat belongs to the genus Catha edulis. It is recognized that the genus consists of only one species; however, the plant exhibits extreme polymorphism.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Street Names: Khat, Qat, Kat, Chat, Miraa, Quaadka) September 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section KHAT (Street Names: Khat, Qat, Kat, Chat, Miraa, Quaadka) September 2019 Introduction: User Population: Khat, Catha edulis, is a flowering shrub native to East Abuse of khat in the United States is most prevalent among Africa and the Arabian-Peninsula. Khat often refers to the immigrants from Somalia, Ethiopia, and Yemen. Abuse of khat is leaves and young shoot of Catha edulis. It has been widely highest in cities with a substantial population of these immigrants. used since the thirteenth century as a recreational drug by the These cities include Boston (MA), Columbus (OH), Dallas (TX), indigenous people of East Africa, the Arabian Peninsula and Detroit (MI), Kansas City (MO), Los Angeles (CA), Minneapolis (MN), throughout the Middle East. Nashville (TN), New York (NY), and Washington D.C. Licit Uses: Illicit Distribution: There is no accepted medical use in treatment for khat in Individuals of Somali, Ethiopian, and Yemeni descent are the the United States. primary transporters and distributors of khat in the United States. The khat is transported from Somalia into the United States and distributed Chemistry and Pharmacology: in the Midwest, West and Southeast (Nashville, Tennessee) regions Khat contains two central nervous system (CNS) of the United States. According to the National Drug Intelligence stimulants, namely cathinone and cathine. Cathinone (alpha- Center, Somali and Yemen independent dealers are distributing khat aminopriopiophenone), which is considered to be the principal in Ann Arbor, Detroit, Lansing and Ypsilanti, Michigan; Columbus, active stimulant, is structurally similar to d-amphetamine and Ohio; Kansas City, Missouri; and Minneapolis/St.
    [Show full text]
  • Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations
    molecules Review Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations Deepak Gupta 1, Deepak Bhatia 2 ID , Vivek Dave 3 ID , Vijaykumar Sutariya 4 and Sheeba Varghese Gupta 4,* 1 Department of Pharmaceutical Sciences, School of Pharmacy, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA; [email protected] 2 ICPH Fairfax Bernard J. Dunn School of Pharmacy, Shenandoah University, Fairfax, VA 22031, USA; [email protected] 3 Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY 14618, USA; [email protected] 4 Department of Pharmaceutical Sciences, USF College of Pharmacy, Tampa, FL 33612, USA; [email protected] * Correspondence: [email protected]; Tel.: +01-813-974-2635 Academic Editor: Peter Wipf Received: 7 June 2018; Accepted: 13 July 2018; Published: 14 July 2018 Abstract: The physicochemical and biological properties of active pharmaceutical ingredients (APIs) are greatly affected by their salt forms. The choice of a particular salt formulation is based on numerous factors such as API chemistry, intended dosage form, pharmacokinetics, and pharmacodynamics. The appropriate salt can improve the overall therapeutic and pharmaceutical effects of an API. However, the incorrect salt form can have the opposite effect, and can be quite detrimental for overall drug development. This review summarizes several criteria for choosing the appropriate salt forms, along with the effects of salt forms on the pharmaceutical properties of APIs. In addition to a comprehensive review of the selection criteria, this review also gives a brief historic perspective of the salt selection processes. Keywords: chemistry; salt; water solubility; routes of administration; physicochemical; stability; degradation 1.
    [Show full text]
  • Toxicology Times
    TOXICOLOGY (800) 677-7995 TIMES www.sdrl.com A FREE Monthly Newsletter for Substance Abuse and Opioid Treatment Volume 5, Issue 7 Programs from San Diego Reference Laboratory July, 2015 Amphetamines (Part 1) Dr. Joseph E. Graas, Scientific Director most often used in inhalers and does not tite, increased stamina and physical energy, Dr. Edward Moore, Medical Director have the central nervous system activity nor increased sexual response/drive, involuntary any addictive properties. All of the com- body movements, increased perspiration, The term “amphetamines” has come to mean pounds that have the structure of hyperactivity, nausea and increased heart rate. a class of endogenous neurotransmitters that phenylethylamine will have this mixture of d This drug is highly addictive and tolerance stimulate the sympathetic nervous system. and l molecules. In the production of these develops quickly. Withdrawal is an extremely This is a broad class of various substituted drugs they are usually noted as a racemic unpleasant experience. A few street names derivatives of phenylethylamine. This grow- mixture, or specifically, as the d or l com- for the drug are amp, speed, crank, dolls and ing class of structurally related molecules may pound. To properly evaluate this family of crystal. also stimulate the sympathetic nervous sys- compounds known as sympathomimetic tem in many different ways, such as affecting amines, amphetamines or phenylethylamine, Methamphetamine was developed by the the re-release of neurotransmitters or pre- it is best done by describing each member of Japanese in 1919 and used during World War venting the re-uptake of neurotransmitters, the class: amphetamine , methampheta- II to help soldiers stay alert and energize hallucinogens, anorectics, bronchodilators mine , phentermine , phenylpropanola- factory workers.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No
    Annex 2B Tariff Schedule of the United States See General Notes to Annex 2B for Staging Explanation HTSUS No. Description Base Rate Staging 0101 Live horses, asses, mules and hinnies: 0101.10.00 -Purebred breeding animals Free E 0101.90 -Other: 0101.90.10 --Horses Free E 0101.90.20 --Asses 6.8% B --Mules and hinnies: 0101.90.30 ---Imported for immediate slaughter Free E 0101.90.40 ---Other 4.5% A 0102 Live bovine animals: 0102.10.00 -Purebred breeding animals Free E 0102.90 -Other: 0102.90.20 --Cows imported specially for dairy purposes Free E 0102.90.40 --Other 1 cent/kg A 0103 Live swine: 0103.10.00 -Purebred breeding animals Free E -Other: 0103.91.00 --Weighing less than 50 kg each Free E 0103.92.00 --Weighing 50 kg or more each Free E 0104 Live sheep and goats: 0104.10.00 -Sheep Free E 0104.20.00 -Goats 68 cents/head A 0105 Live poultry of the following kinds: Chickens, ducks, geese, turkeys and guineas: -Weighing not more than 185 g: 0105.11.00 --Chickens 0.9 cents each A 0105.12.00 --Turkeys 0.9 cents each A 0105.19.00 --Other 0.9 cents each A -Other: 0105.92.00 --Chickens, weighing not more than 2,000 g 2 cents/kg A 0105.93.00 --Chickens, weighing more than 2,000 g 2 cents/kg A 0105.99.00 --Other 2 cents/kg A 0106 Other live animals: -Mammals: 0106.11.00 --Primates Free E 0106.12.00 --Whales, dolphins and porpoises (mammals of the order Cetacea); manatees and dugongs (mammals of the order Sirenia) Free E 0106.19 --Other: 2B-Schedule-1 HTSUS No.
    [Show full text]
  • 9.18.19 Didactic
    STIMULANTS- PART I Michael H. Baumann, Ph.D. Designer Drug Research Unit (DDRU), Intramural Research Program, NIDA, NIH Baltimore, MD 21224 Chronology of Stimulant Misuse 1. 1980s: Cocaine 2. 1990s: Ecstasy 3. Summary 2 Topics Covered for Each Substance Chemistry Formulations and Methods of Use Pharmacokinetics and Metabolism Desired and Adverse Effects Chronic and Withdrawal Effects Neurobiology Treatments 1980s: Cocaine Cocaine, a Plant-Based Alkaloid Andean Cocaine is Trafficked Globally UNODC World Drug Report, 2012 Formulations and Methods of Use Cocaine Free Base (i.e., Crack) Smoking of free base “rock” using pipes Cocaine HCl Intravenous injection of solutions using needle and syringe Intranasal snorting of powder Pharmacokinetics and Metabolism Pharmacokinetics Smoked drug reaches brain within seconds Intravenous drug reaches brain within seconds Intranasal drug reaches brain within minutes Metabolism Ester hydrolysis to benzoylecgonine Ecgonine methyl ester Cone, 1995 Rate Hypothesis of Drug Reward Smoked and Intravenous Routes Faster rate of drug entry into the brain Enhanced subjective and rewarding effects Intranasal and Oral Routes Slower rate of drug entry into the brain Reduced subjective and rewarding effects Desired Effects Enhanced Mood and Euphoria Increased Attention and Alertness Decreased Need for Sleep Appetite Suppression Sexual Arousal Adverse Effects Psychosis Tachycardia, Arrhythmias, Heart Attack Hypertension, Stroke Hyperthermia, Rhabdomyolysis Multisystem Organ Failure Tolerance-
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Whoexpertcommittee Ondrugdependence
    Thisreportcontainsthecollectiveviewsof an international groupof expertsanddoesnotnecessarilyrepresentthedecisions Tile World 1lealth Organization is a specialized agcncyof the United Nations with orthestatedpolicyof theWorldHealthOrganization primary responsibility for international health'matters anti public health. Through this organization, which was created in 1948, the health professions of' some I65 countries exchange their knowledge and experience with the aim of making possible will permit them lo lead a socially and ccommlically productive lil_. WHOExpertCommittee By means of direct technical cooperation whh its Membcr Stales, and by stimt,- hhensiveding suchhealthcooperationservices, tamonghe preventionthem, WllOprornotesthcdevclopmcntorcomprc-anti control of diseascs, thc improvement o[ environmental conditions, tile development of health manpower, the coordination onDrugDependence anti development of biomedical and health services research, and thc planning and implementation of health programmes. These broad fiekls of endeavour encompass a wide variety of activities, such as developing systems of primary health cltre that reach the whole population of Mem- ber countries; promoting tile health of`mothers and children; combating malnutrition; controlling malaria and other communicable diseases including tuberculosis and leprosy; having achieved tile eradication or smallpox, promoting mass immunization against a numbcr of other preventable diseases; improving mental health; providing safe water supplies: anti training health
    [Show full text]